Clinical Trials on Nail Psoriasis in Argentina

Total 48 results

Liga Panamericana de Asociaciones de Reumatologia...

Recruiting

PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors (PREJAK)

Arthritis, Rheumatoid | Arthritis, Psoriatic | Spondyloarthritis

Argentina
Bristol-Myers Squibb

Terminated

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Psoriatic Arthritis

Argentina, France, Italy, United States, Canada, Belgium, Netherlands, Australia, Germany, South Africa, Spain, Norway
Novartis Pharmaceuticals

Completed

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) (PDUS)

Psoriatic Arthritis

Germany, Netherlands, Spain, Argentina, Belgium, Colombia, Italy, United States, United Kingdom, Ireland, France, Mexico, Canada, Austria, Czechia, Hungary, Norway
Sun Pharmaceutical Industries Limited

Completed

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

Psoriatic Arthritis

United States, Argentina, Hungary, Mexico, Poland, Russian Federation, Spain, Ukraine
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Bristol-Myers Squibb

Completed

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis (ASTRAEA)

Psoriatic Arthritis

Italy, South Africa, United States, Spain, Germany, Mexico, Israel, France, Greece, Canada, Brazil, Czechia, Peru, Poland, Argentina, Colombia, Chile
Janssen Research & Development, LLC

Recruiting

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)

Arthritis, Juvenile

United States, France, United Kingdom, Turkey, Spain, Argentina, Germany, Italy, Poland, Denmark
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Psoriatic Arthritis

Germany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia
Novartis Pharmaceuticals

Completed

Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext)

Psoriatic Arthritis

United Kingdom, Belgium, Germany, Thailand, Israel, United States, Philippines, Singapore, Italy, Argentina, Russian Federation, Bulgaria, Czechia, Australia, Canada, Poland, Brazil, Slovakia
Amgen

Completed

Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

Psoriatic Arthritis

United States, Hungary, Czechia, Mexico, Russian Federation, Puerto Rico, Canada, Greece, Poland, Bulgaria, Spain, United Kingdom, Argentina, Latvia, Chile, France, Portugal, South Africa
Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

Psoriatic Arthritis

United States, United Kingdom, India, Austria, Denmark, Netherlands, Spain, Germany, Thailand, Israel, Argentina, Greece, Philippines, Latvia, Italy, Guatemala, Russian Federation, Hungary, Ireland, Vietnam, Czechia, Canada, Sweden, M... and more
Bristol-Myers Squibb

Active, not recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Psoriatic Arthritis

United States, Australia, Belgium, Spain, Argentina, China, Canada, Colombia, Czechia, Germany, Hungary, Italy, Japan, Mexico, Poland, Russian Federation, Taiwan, United Kingdom
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis (SPIRIT-H2H)

Psoriatic Arthritis

Belgium, Hungary, Canada, India, Israel, Italy, Australia, Netherlands, United Kingdom, Mexico, Switzerland, South Africa, Poland, Finland, Argentina, France, Germany, Ukraine, Spain, Austria, Denmark, Sweden
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

Psoriatic Arthritis

France, Belgium, Korea, Republic of, Netherlands, United Kingdom, Germany, Taiwan, Portugal, Denmark, Saudi Arabia, Czechia, Sweden, Switzerland, Argentina, Poland, Italy, Hungary, Spain, Australia, Austria, Colombia, Finland, Former... and more
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
Bristol-Myers Squibb

Recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Psoriatic Arthritis

Italy, United States, Australia, Argentina, Brazil, Czechia, France, Hungary, Mexico, Russian Federation, China, Poland, Finland, Colombia, United Kingdom, Bulgaria, Taiwan, Chile, Romania, Spain, Ireland
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Palmoplantar Psoriasis | Genital Psoriasis

United States, Germany, Spain, Italy, Poland, Argentina, Canada
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Pfizer

Completed

Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis (PRISTINE)

Psoriasis | Plaque Psoriasis

Spain, Taiwan, Germany, Korea, Republic of, Belgium, Greece, Hungary, Argentina, Austria, Czech Republic, Italy, Mexico, Thailand
Boehringer Ingelheim

Active, not recruiting

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

Generalized Pustular Psoriasis

United States, Taiwan, Korea, Republic of, Germany, Malaysia, Belgium, Chile, China, France, Italy, Japan, Mexico, Philippines, Russian Federation, Spain, Thailand, Tunisia, Vietnam, Turkey, Argentina
UCB BIOSCIENCES GmbH

Completed

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Arthritis, Psoriatic

Germany, United States, Argentina, Belgium, Brazil, Canada, Czechia, France, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)

Arthritis, Psoriatic

Belgium, Korea, Republic of, Austria, Germany, Japan, Mexico, Greece, United Kingdom, Italy, Sweden, Spain, France, Taiwan, Netherlands, Canada, Argentina, Australia, Colombia, Russian Federation, Switzerland
Novartis Pharmaceuticals

Completed

Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis (STEPin)

Plaque Psoriasis

Spain, United Kingdom, Estonia, Germany, Bulgaria, Finland, Hungary, Poland, Argentina, Canada, Denmark, Switzerland, Sweden
Boehringer Ingelheim

Completed

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

Spain, Taiwan, Thailand, Korea, Republic of, Germany, Malaysia, United States, Argentina, Belgium, Chile, China, France, Greece, Italy, Japan, Mexico, Netherlands, Philippines, Russian Federation, South Africa, Tunisia, Turkey, Vietnam
Novartis Pharmaceuticals

Completed

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

Moderate and Severe Plaque Psoriasis

United States, Argentina, Germany, Belgium, Italy, United Kingdom, Turkey, Guatemala, Australia
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

Arthritis, Psoriatic

Italy, Germany, Taiwan, United States, Malaysia, Turkey, Georgia, Canada, Hong Kong, Portugal, Denmark, Israel, Philippines, Thailand, Bulgaria, Australia, Czechia, Hungary, Poland, Russian Federation, Ukraine, Spain, Argentina, United... and more
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Australia, Mexico, Canada, United Kingdom, France, Argentina, Japan, Poland, Spain, Korea, Republic of, Brazil, Germany, Romania
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) (ICONIC-TOTAL)

Plaque Psoriasis

United States, Korea, Republic of, Hungary, United Kingdom, Canada, Germany, Poland, Turkey, Taiwan, Spain, Argentina
Janssen Research & Development, LLC

Recruiting

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)

Arthritis, Psoriatic

Israel, Turkey, United States, Hungary, Spain, Australia, Bulgaria, Czechia, Malaysia, Poland, Puerto Rico, Russian Federation, Ukraine, Argentina
Eli Lilly and Company

Completed

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (IXORA-P)

Plaque Psoriasis

Argentina, Puerto Rico, United States, Australia, Taiwan, Japan, Hungary, Korea, Republic of, Mexico, Germany, Poland, Romania, Czechia, Canada
Eli Lilly and Company

Completed

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis (Ixora-peds)

Plaque Psoriasis

United States, Spain, Puerto Rico, Czechia, Canada, Germany, France, Poland, Hungary, Mexico, Russian Federation, Argentina, Netherlands
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)

Plaque Psoriasis

Germany, United States, Hungary, Italy, Turkey, Korea, Republic of, United Kingdom, China, Taiwan, Poland, Canada, France, Japan, Australia, Spain, Argentina
Janssen Research & Development, LLC

Recruiting

A Long-term Extension Study of Ustekinumab in Pediatric Participants (UNITED)

Crohn Disease | Arthritis, Psoriatic | Colitis, Ulcerative

Belgium, France, United States, Hungary, Japan, United Kingdom, Germany, Poland, Argentina
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Korea, Republic of, United Kingdom, United States, Poland, Germany, Brazil, Spain, Taiwan, Hungary, Japan, Canada, Argentina, Australia
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (FIXTURE)

Chronic Plaque Psoriasis

Germany, United States, Colombia, Italy, Spain, Belgium, Egypt, Hungary, Australia, Singapore, France, Sweden, Guatemala, Philippines, Korea, Republic of, United Kingdom, Argentina, Poland, Romania, Canada, Iceland, India, Finland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

Moderate to Severe Plaque-type Psoriasis

United States, Colombia, Estonia, Japan, Taiwan, Israel, Canada, Lithuania, Argentina, Latvia, Iceland, Mexico
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
AbbVie

Active, not recruiting

Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE)

Chronic Plaque Psoriasis

Argentina, Australia, Austria, Canada, Colombia, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Spain, Switzerland, United Arab Emirates, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

Psoriasis

Argentina, Canada, Guatemala, Mexico, Brazil, Costa Rica, Dominican Republic, Panama
Eli Lilly and Company

Completed

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (UNCOVER-3)

Psoriasis

United States, Hungary, Germany, Canada, Mexico, Bulgaria, Russian Federation, Poland, Argentina, Chile
Eli Lilly and Company

Completed

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Psoriasis

United States, Spain, Puerto Rico, Canada, France, Korea, Republic of, Australia, Italy, Israel, Japan, Germany, Argentina, Czechia, Hungary, Poland, United Kingdom
Eli Lilly and Company

Terminated

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Psoriasis

United States, Spain, Puerto Rico, Canada, France, Korea, Republic of, Germany, Australia, Italy, Israel, Poland, Japan, Argentina, Hungary, Taiwan, United Kingdom, Mexico, Czechia, Russian Federation
Pfizer

Completed

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Denmark, Slovakia, Canada, Australia, Argentina, Bulgaria, Netherlands, United Kingdom, Brazil, Finland, Greece
Pfizer

Terminated

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Spain, Korea, Republic of, Taiwan, Canada, Poland, Belgium, Denmark, Germany, Serbia, United Kingdom, France, Czechia, Hungary, Mexico, Colombia, Russian Federation, Croatia, Singapore, Australia, Austria, Slovakia, S... and more
Pfizer

Completed

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

Belgium, Spain, Germany, France, Hungary, Russian Federation, Singapore, Argentina, Austria, Bosnia and Herzegovina, Bulgaria, Chile, Colombia, Croatia, Czechia, Denmark, Hong Kong, Israel, Korea, Republic of, Netherlands, Poland, Slovaki... and more
Janssen Scientific Affairs, LLC

Active, not recruiting

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Psoriasis

United States, Australia, Ukraine, Belgium, Taiwan, Spain, Austria, Colombia, Israel, Portugal, Slovenia, Japan, Canada, Greece, Korea, Republic of, Argentina, Chile, Netherlands, Sweden, Slovakia, Czechia, Mexico
Centocor, Inc.
Centocor BV

Completed

A Long-term Safety Study of Infliximab (Remicade)

Arthritis, Rheumatoid | Psoriasis | Crohn Disease

United States, Canada, France, Germany, Poland, United Kingdom, Belgium, Spain, Argentina, Israel, Switzerland, Finland, Sweden, Netherlands, Austria, Hungary, Ireland, Norway, Denmark

Clinical Trials on Nail Psoriasis in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations